Experimental data suggest that angiotensin II-antagonists reduce the atrial expression of
prothrombotic adhesion molecules and oxidative stress parameters. The present study is
designed to investigate the effects on angiotensin II-antagonist irbesartan to reduce the
amounts of circulating oxidative stress markers and adhesion molecules in patients with
persistent atrial fibrillation.